HeXun Biosciences Co Ltd

HeXun Biosciences maintains a strong liquidity position with a current ratio of 9.75, indicating a high ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity risk. The price-to-book ratio of 3.85 suggests the market values the company at a premium to its book value, while the price-to-earnings ratio of 25.49 indicates a moderate valuation relative to earnings. In terms of profitability, HeXun Biosciences reports a return on equity (ROE) of 15.09% and a return on assets (ROA) of 13.37%, both exceeding the typical thresholds for the Biotechnology & Medical Research industry. The company's operating margin of 40.26% (calculated from operating income of TWD 118,037,000 and revenue of TWD 293,225,000) is robust, reflecting efficient cost management. The company's revenue is primarily concentrated in domestic markets, with no disclosed international segments. This geographic concentration may limit growth opportunities and increase exposure to local economic and regulatory risks. The company's business is segmented into new drug development and sales, contract development and manufacturing services, and other services, with no detailed revenue breakdown provided. Looking ahead, the company is projected to maintain a stable revenue trajectory, with no significant growth or decline expected in the next fiscal year. The capital expenditure of -TWD 27,379,000 indicates a reduction in investment, which may signal a focus on cost optimization or a shift in strategic priorities. The company's risk assessment highlights a medium liquidity risk and a low dilution risk, with no immediate pressure for equity issuance. Recent filings and transcripts do not indicate any material events or strategic shifts. The company continues to focus on its core drug development and contract manufacturing services, with no disclosed major partnerships or product launches in the latest reporting period.